Fuse Medical (FZMD) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Entity Registrant Name	Fuse Medical, Inc.
Entity Central Index Key	0000319016
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		72,895,793
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Tax Identification Number	59-1224913
Entity File Number	000-10093
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1565 N. Central Expressway
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Richardson
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75080
City Area Code	469
Local Phone Number	862-3030
Title of 12(b) Security	Common Stock
Trading Symbol	FZMD

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 603,996	$ 553,190
Accounts receivable, net of allowance of $395,666 and $498,261, respectively	2,964,744	3,528,992
Inventories	9,357,282	8,736,474
Prepaid expenses and other current assets	95,331	5,921
Total current assets	13,021,353	12,824,577
Property and equipment, net	351,611	7,251
Long term accounts receivable, net of allowance of $3,757,591 and $3,355,391, respectively	2,450,569	2,182,437
Intangible assets, net	1,256,410	1,317,341
Goodwill	1,972,886	1,972,886
Total assets	19,052,829	18,304,492
Current liabilities:
Accounts payable	4,781,712	4,461,641
Accrued expenses	3,953,587	2,898,068
Convertible notes payable - related parties	150,000	150,000
Notes payable - related parties	200,000	200,000
Senior secured revolving credit facility	2,240,171	2,432,770
Total current liabilities	11,325,470	10,142,479
Earn-out liability	11,593,832	11,593,832
Total liabilities	22,919,302	21,736,311
Commitments and contingencies
Stockholders' equity (accumulated deficit)
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized, 72,895,793 shares issued and outstanding as of June 30, 2022 and December 31, 2021.	728,958	728,958
Additional paid-in capital	1,472,368	1,455,422
Accumulated deficit	(6,067,799)	(5,616,199)
Total stockholders' equity (accumulated deficit)	(3,866,473)	(3,431,819)
Total liabilities and stockholders' equity (accumulated deficit)	$ 19,052,829	$ 18,304,492

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Net of allowance, accounts receivable	$ 395,666	$ 498,261
Net of allowance, long term receivable	$ 3,757,591	$ 3,355,391
Preferred Stock Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	20,000,000	20,000,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	100,000,000	100,000,000
Common Stock Shares Issued	72,895,793	72,895,793
Common Stock Shares Outstanding	72,895,793	72,895,793

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net revenues	$ 4,668,290	$ 5,665,015	$ 9,222,628	$ 10,105,774
Cost of revenues	1,723,642	2,219,608	3,348,833	4,073,473
Gross profit	2,944,648	3,445,407	5,873,795	6,032,301
Operating expenses:
Selling, general, administrative and other	1,422,768	2,021,576	3,132,309	3,456,887
Commissions	1,463,859	1,834,372	2,969,530	3,399,125
Depreciation and amortization	109,642	15,465	144,044	32,258
Total operating expenses	2,996,269	3,871,413	6,245,883	6,888,270
Operating loss	(51,621)	(426,006)	(372,088)	(855,969)
Other (income) expense:
Interest expense	36,527	16,048	69,485	35,048
Gain on Payroll Protection Loan extinguishment		(361,400)		(361,400)
Total other (income) expense	36,527	(345,352)	69,485	(326,352)
Net loss before income tax	(88,148)	(80,654)	(441,573)	(529,617)
Income tax expense	5,171	4,826	10,027	9,186
Net loss	$ (93,319)	$ (85,480)	$ (451,600)	$ (538,803)
Net loss per common share - basic	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding - basic	70,321,566	70,221,566	70,321,566	70,221,566

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings/ (Deficit) [Member]
Beginning Balance, Amount at Dec. 31, 2020	$ (2,112,841)	$ 731,245	$ 1,184,222	$ (4,028,308)
Beginning Balance, Shares at Dec. 31, 2020		73,124,458
Stock compensation expense	115,948		115,948
Net loss	(453,323)			(453,323)
Ending Balance, Amount at Mar. 31, 2021	(2,450,216)	$ 731,245	1,300,170	(4,481,631)
Ending Balance, Shares at Mar. 31, 2021		73,124,458
Beginning Balance, Amount at Dec. 31, 2020	(2,112,841)	$ 731,245	1,184,222	(4,028,308)
Beginning Balance, Shares at Dec. 31, 2020		73,124,458
Net loss	(538,803)
Ending Balance, Amount at Jun. 30, 2021	(2,465,621)	$ 731,245	1,370,245	(4,567,111)
Ending Balance, Shares at Jun. 30, 2021		73,124,458
Beginning Balance, Amount at Mar. 31, 2021	(2,450,216)	$ 731,245	1,300,170	(4,481,631)
Beginning Balance, Shares at Mar. 31, 2021		73,124,458
Stock compensation expense	70,075		70,075
Net loss	(85,480)			(85,480)
Ending Balance, Amount at Jun. 30, 2021	(2,465,621)	$ 731,245	1,370,245	(4,567,111)
Ending Balance, Shares at Jun. 30, 2021		73,124,458
Beginning Balance, Amount at Dec. 31, 2021	(3,431,819)	$ 728,958	1,455,422	(5,616,199)
Beginning Balance, Shares at Dec. 31, 2021		72,895,793
Stock compensation expense	12,844		12,844
Net loss	(358,281)			(358,281)
Ending Balance, Amount at Mar. 31, 2022	(3,777,256)	$ 728,958	1,468,266	(5,974,480)
Ending Balance, Shares at Mar. 31, 2022		72,895,793
Beginning Balance, Amount at Dec. 31, 2021	(3,431,819)	$ 728,958	1,455,422	(5,616,199)
Beginning Balance, Shares at Dec. 31, 2021		72,895,793
Net loss	(451,600)
Ending Balance, Amount at Jun. 30, 2022	(3,866,473)	$ 728,958	1,472,368	(6,067,799)
Ending Balance, Shares at Jun. 30, 2022		72,895,793
Beginning Balance, Amount at Mar. 31, 2022	(3,777,256)	$ 728,958	1,468,266	(5,974,480)
Beginning Balance, Shares at Mar. 31, 2022		72,895,793
Stock compensation expense	4,102		4,102
Net loss	(93,319)			(93,319)
Ending Balance, Amount at Jun. 30, 2022	$ (3,866,473)	$ 728,958	$ 1,472,368	$ (6,067,799)
Ending Balance, Shares at Jun. 30, 2022		72,895,793

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (451,600)	$ (538,803)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	144,044	32,258
Stock based compensation	16,946	186,023
Provision for bad debts and discounts	(102,595)	153,517
Provision for long term accounts receivable	402,200	659,442
Provision for slow moving inventory	(94,595)	(433,505)
Gain on Payroll Protection Program Loan extinguishment		(361,400)
Changes in operating assets and liabilities:
Accounts receivable	666,843	1,222,444
Inventories	(526,213)	(897,793)
Prepaid expenses and other current assets	(89,410)	(36,895)
Long term accounts receivable	(670,332)	(1,118,958)
Accounts payable	320,071	1,068,299
Accrued expenses	1,055,519	234,789
Net cash provided by operating activities	670,878	169,418
Cash flows from investing activities
Purchase of property and equipment	(422,973)
Net cash (used in) investing activities	(422,973)
Cash flows from financing activities
Net payments on CNH senior secured revolving credit facility	(192,599)
Payments of deferred financing costs	(4,500)
Net cash (used in) financing activities	(197,099)
Net increase in cash	50,806	169,418
Cash and cash equivalents - beginning of period	553,190	1,187,458
Cash and cash equivalents - end of period	603,996	1,356,876
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 50,796	$ 21,235

Nature of Operations

Nature of Operations	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations	Note 1. Nature of Operations Overview Fuse Medical, Inc., a Delaware corporation (the “Company”), is a manufacturer and national distributor of medical devices and surgical implants for the orthopedic market. The Company acquired CPM Medical Consultants, LLC (“CPM”) in December 2017 (the “CPM Acquisition”), in which the Company was the legal acquirer and CPM was deemed the accounting acquirer. In August 2018, the Company completed the acquisition of Palm Springs Partners, LLC d/b/a Maxim Surgical (“Maxim” and such transactions the “Maxim Acquisition”). CPM and, until its dissolution, Maxim survived as the Company’s wholly-owned subsidiaries and subsequent to the completion of each acquisition, CPM, Maxim and Company operations are consolidated. Maxim was subsequently dissolved and terminated on December 20, 2019. Nature of Business The Company is a manufacturer, distributor, and wholesaler of medical device implants, offering a broad portfolio of orthopedic implants and biologics including: (i) internal and external fixation products; (ii) upper and lower extremity plating and total joint reconstruction implants; (iii) soft tissue fixation and augmentation for sports medicine procedures; (iv) spinal implants for trauma, degenerative disc disease and deformity indications; and (v) a wide array of osteo-biologics and regenerative products, which include human allografts, substitute bone materials, tendons, and regenerative tissues. All of the Company’s medical devices are approved by the FDA for sale in the United States, and all of the Company’s Biologics suppliers are licensed tissue banks accredited by the American Association of Tissue Banks. The Company’s broad portfolio of Orthopedic Implants and Biologics provide high-quality products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers, which include hospitals, medical facilities, and sub-distributors. The Company operates under exclusive and non-exclusive agreements with certain vendors and supply partners in the geographic territories the Company serves. The Company continuously reviews and expands its product lines to ensure that they offer a comprehensive, high-quality and cost-effective selection of Orthopedic Implants and Biologics so that the Company can be more relevant to its customer needs while continuing to grow its existing customer base. Additionally, the Company continues to grow its manufacturing operations, both by internal product development as well as the acquisition of existing FDA cleared devices. Basis of Presentation The interim unaudited condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2021, was derived from the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2021 (“2021 Annual Report”), filed with the SEC pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on March 31, 2022. These interim unaudited condensed consolidated financial statements should be read in conjunction with the 2021 Annual Report. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period as the Company has historically experienced seasonal trends with greater revenue and volume between the last two calendar quarters compared to the first two calendar quarters of the year.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Note 2. Significant Accounting Policies Principles of Consolidation The interim unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, CPM. Intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of the interim unaudited condensed consolidated financial statements in accordance with GAAP, requires the Company to make estimates and assumptions that affect the Company’s reported amounts in the interim unaudited condensed consolidated financial statements. Actual results could differ from those estimates. Significant estimates on the accompanying interim unaudited condensed consolidated financial statements include the allowance for doubtful accounts, valuation of inventories, the Company’s effective income tax rate, the fair value calculations of stock-based compensation, goodwill, finite lived intangibles and the earn-out (“Earn-Out”) liability. Segment Reporting In accordance with Accounting Standards Codification (“ASC”) No. 280, “ Segment Reporting Reclassification Medical instrument depreciation was previously reported as a component of cost of revenues in the Company’s accompanying consolidated statements of operations. Medical instruments are orthopedic devices that are utilized in all cases where our Orthopedic Implants are implanted. Subsequent to December 31, 2021, the Company began depreciating these medical instruments over 3 years and have now reclassed this depreciation expense to depreciation and amortization in the accompanying consolidated statements of operations. Loss Per Common Share Loss per common share, basic is calculated by dividing the net income/(loss) attributable to common stockholders by the weighted-average number of common stock, par value $0.01 (“Common Stock”), outstanding during the period, without consideration of Common Stock equivalents. Shares of restricted stock are included in the basic weighted-average number of Common Stock outstanding from the time they vest. Diluted loss per common share is computed by dividing net income/(loss) by the weighted-average number of Common Stock equivalents outstanding for the period determined using the treasury stock method. For the six months ended June 30, 2022 and 2021, the Company excluded the effects of outstanding stock options, convertible notes and, to the extent vested, restricted stock as their effects were antidilutive due to the Company’s operating loss during these periods. (See Note 9, “Stockholders’ Equity” for the terms and conditions of restricted stock). Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets; Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. In connection with the CPM Acquisition, the Company initially recorded a $19,244,543 liability related to the Earn-Out portion of the purchase consideration. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability is evaluated each reporting period and changes in its fair value are included in the Company’s earnings. The Earn-Out payments are based on the financial performance of the Company between the period of January 1, 2018 , and December 31, 2034 . The base amount of the Earn-Out is up to $ 16,000,000 with an additional bonus payment up to $ 10,000,000 . The payments of the base and bonus Earn-Out amounts are subject to the Company meeting certain earnings thresholds as detailed in the CPM Acquisition Agreement. The Earn-Out liability, which represents contingent consideration associated with the CPM Acquisition, is recorded as a liability. This liability is subject to re-measurement to fair value at each reporting date until the contingency is resolved and the changes in fair value are recognized in the consolidated statements of operations at each reporting period. The Earn-Out was remeasured to fair value under the probability weighted income approach. As a result, the fair value of the Earn-Out liability was reduced by $342,168 from $11,936,000 to $11,593,832 in 2021 and increased by $290,635 from $11,645,365 to $11,936,000 in 2020 and reflected as “Change in fair value of contingent purchase consideration” on our Consolidated Financial Statements. There was no change in the Earn-Out liability for the six months ended June 30, 2022 and there were no significant changes in the Level 3 inputs from those utilized at December 31, 2021. The required earnings thresholds have not been met from inception of the agreements through June 30, 2022, and as such, there have been no payments required for either the base or bonus Earn-Out tranches. Financial Instruments The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded values of notes payable approximate their respective fair values based upon their effective interest rates. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at June 30, 2022 and December 31, 2021. The Company’s cash is concentrated in one large financial institution. The amount of cash held at the financial institution may at times exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any financial institution losses from inception through June 30, 2022. As of June 30, 2022 and December 31, 2021, there were deposits of $523,993 and $594,536 , respectively, Accounts Receivable and Allowances Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable and an allowance for contractual discount pricing. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other factors considered by the Company. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery. The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstances warrant, the Company estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying interim unaudited condensed consolidated statements of operations. When accounts are deemed uncollectible, they are often referred to the Company’s outside legal firm for litigation. Accounts deemed uncollectible are written-off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. Accounts deemed uncollectible are removed from the Company’s accounts receivable portfolio, with a corresponding offset to the allowance for doubtful accounts receivable. The Company may record additional allowances for doubtful accounts based on known trends and expectations to ensure the Company’s accounts receivable portfolio is recorded at net realizable value. Specific allowances are re-evaluated and adjusted as additional facts and information become available. Previously written-off accounts receivable subsequently collected are recognized as a reduction of bad debt expense when funds are received. The Company estimates its allowance for contractual discount pricing, by evaluating specific accounts where information indicates the customer is offered contractual pricing and discount allowances. In these arrangements, the Company uses assumptions and judgement, based on the best available facts and circumstances to record a specific allowance for the amounts due from those customers. The allowance is offset by a corresponding reduction to revenue. These specific allowances are re-evaluated, analyzed, and adjusted as additional information becomes available to determine the total amount of the allowance. The Company may record additional allowances based on trends and expectations to ensure the Company’s accounts receivable portfolio is recorded at net realizable value. Inventories Inventories are stated at the lower of cost or net realizable value (first-in, first-out) which includes an allowance for slow-moving inventory, expired inventory, and inventory obsolescence. Inventories consist entirely of finished goods and include internal and external fixation products; upper and lower extremity plating and total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, “Orthopedic Implants”) and osteo-biologics and regenerative tissue which include human allografts, substitute bone materials, tendons, as well as amniotic tissues (collectively, “Biologics”). The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. In cases where the market values are less than the carrying value, a write-down is recognized equal to an amount by which the carrying value exceeds the market value of inventories. Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets per the following table. Expenditures for additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. The Company reviews long-lived assets for impairment annually or whenever changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Category Useful Life Computer equipment and software 3 years Furniture and fixtures 3 years Office equipment 3 years Medical instruments 3 years Software 3 years Upon the retirement or disposition of property and equipment, the related cost and accumulated depreciation is removed. A gain is recorded when consideration received is more than the disposed asset’s cost, net of depreciation, and a loss is recorded when consideration received is less than the disposed asset’s cost, net of depreciation. Long-Lived Assets The Company reviews other long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows, which is at the individual asset level or the asset group level. The undiscounted cash flows expected to be generated by the related assets are estimated over their useful life based on updated projections. If the evaluation indicates that the carrying amount of the assets may not be recoverable, any potential impairment is measured based upon the fair value of the related assets or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale, if any, are recorded at the lower of carrying amount or fair value less costs to sell. Goodwill and Other Intangible Assets Goodwill is determined based on an acquisition purchase price in excess of the fair value of identified net assets acquired. Intangible assets with lives restricted by contractual, legal, or other means are amortized over their useful lives. Goodwill is not amortized, but is tested in the fourth quarter each year for impairment, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. The Company performs its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. ASC 350-30-35-18, “ Intangible assets not subject to amortization The Company’s intangible assets subject to amortization consist primarily of acquired non-compete agreements, funds to secure Credit and Security Agreement (the “Credit Agreement”) with CNH Finance Fund I, L.P., and customer relationships. Amortization expense is calculated using the straight-line method over the asset’s expected useful life. Revenue Recognition The Company’s revenues are generated from the sales of Orthopedic Implants and Biologics to support orthopedic surgeries. The Company obtains purchase orders from its customers for the sale of its products which sets forth the general terms and conditions including line item pricing and payment terms (generally due upon receipt). The Company recognizes revenue when its customers obtain control over the assets (generally when the title passes upon shipment or when a product is utilized in a surgery), and it is probable that the Company will collect substantially all the amounts due. Individual promised goods are the Company’s only performance obligation. Due to the nature of its products, the Company’s product returns have been historically immaterial. The Company includes shipping and handling fees in net revenues. Shipping and handling costs are associated with outbound freight after control over a product has transferred to a customer and are accounted for as a fulfillment cost and are included in cost of goods sold on the Company’s accompanying interim unaudited condensed consolidated statements of operations. Revenue Differentiation The Company measures sales volume based on medical procedures in which the Company’s products are sold and used (“Cases”). The Company considers Cases resulting from direct sales to medical facilities to be retail cases (“Retail Cases”) and Cases resulting from sales to third parties, such as non-medical facilities, distributors, or sub-distributors, to be wholesale cases (“Wholesale Cases”). Some of the Company’s sales for Wholesale Cases are on a consignment basis with a third party. When consigned, the revenue is not recorded until the device is implanted in a patient during surgery. In the Company’s industry, Retail Cases are typically sold at higher price points than Wholesale Cases, resulting in greater revenue and gross profit per Case. Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Category Retail $ 4,500,975 $ 5,159,510 $ 8,794,731 $ 9,143,388 Wholesale 167,315 505,505 427,897 962,386 Total $ 4,668,290 $ 5,665,015 $ 9,222,628 $ 10,105,774 Cost of Revenues Cost of revenues consists of (i) cost of goods sold, (ii) freight and shipping costs for items sold to customers, (iii) cost of storage, (iv) inventory shrink, and (v) an estimate for slow-moving inventory, expired inventory, and inventory obsolescence. Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors, and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro-rata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued, both effective and not yet effective. Other recent accounting pronouncements issued by the Financial Accounting Standards Board, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by the Company to have a material impact on the Company's present or future consolidated financial statements.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property Plant And Equipment [Abstract]
Property and Equipment	Note 3. Property and Equipment Property and equipment consisted of the following at June 30, 2022 and December 31, 2021: June 30, 2022 December 31, 2021 Computer equipment and software $ 20,249 $ 20,249 Medical instruments 422,973 - Office equipment - - Property and equipment costs 443,222 20,249 Less: accumulated depreciation (91,611 ) (12,998 ) Property and equipment, net $ 351,611 $ 7,251 Depreciation expense for the three months ended June 30, 2022 and 2021 was $56,209 and $2,832, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 was $78,613 and $6,992, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 4. Goodwill and Intangible Assets The following table summarizes the Company’s goodwill and other intangible assets: June 30, 2022 December 31, 2021 Amortization period (years) Intangible assets: 510(k) product technology $ 704,380 $ 704,380 Indefinite Customer relationships 555,819 555,819 11 CNH Credit Agreement 240,858 236,358 3 Total intangible assets 1,501,057 1,496,557 Less: accumulated amortization (244,647 ) (179,216 ) Intangible assets, net 1,256,410 1,317,341 Goodwill $ 1,972,886 $ 1,972,886 Indefinite Amortization expense for the three months ended June 30, 2022 and 2021 was $32,715 and $12,633, respectively. Amortization expense for the six months ended June 30, 2022 and 2021, was $65,431 and $25,266. Company’s intangible assets subject to amortization consist primarily of acquired non-compete agreements, funds to secure the Credit Agreement with CNH Finance Fund I, L.P., and customer relationships.

Senior Secured Revolving Credit

Senior Secured Revolving Credit Facility	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Senior Secured Revolving Credit Facility	Note 5. Senior Secured Revolving Credit Facility On December 29, 2017, the Company became party to the Senior Secured Revolving Credit Facility (“RLOC”) with ZB, N.A., d/b/a Amegy Bank (“Amegy Bank”). The RLOC established an asset-based senior secured revolving credit facility in the amount of $5,000,000. The RLOC contained customary representation, warranties, covenants, events of default, and was collateralized by substantially all of the Company’s assets. The Company’s Chairman of the Board and President initially personally guaranteed fifty percent (50%) of the outstanding RLOC amount. On September 21, 2018, the Company executed the First Amendment to the RLOC with Amegy Bank (the “First Amendment”). The First Amendment (i) waived the Company’s events of default under the RLOC through the fiscal quarter ended September 30, 2018, and (ii) added a covenant that the Company achieve quarterly net income of $ 700,000 or more for the fiscal quarter ending on September 30, 2018. On November 19, 2018, the Company executed the Second Amendment to the RLOC with Amegy Bank (the “Second Amendment”). The Second Amendment (i) waived the Company’s events of default under the RLOC, (ii) On May 9, 2019, the Company executed the Third Amendment to the RLOC with Amegy Bank (the “Third Amendment”). Pursuant to the Third Amendment, Amegy Bank (i) waived the Company’s events of default under the RLOC, (ii) reduced the aggregate limit of the RLOC to $3,500,000, (iii) reduced the limit of credit card exposure to $500,000, (iv) reduced the borrowing base component of Inventory to 30%, (v) amended the financial covenants to state that the Company will not permit EBITDA to be less than $100,000 for the fiscal quarter ending June 30, 2019 and $500,000 for the fiscal quarter ending September 30, 2019, and (vi) rescinded the Loan Sweep Feature, requiring the Company to give notice of each requested loan by delivery of Advance Request to Amegy Bank. On December 18, 2019, the Company executed the Fourth Amendment to the RLOC with Amegy Bank (the “Fourth Amendment”). Pursuant to the Fourth Amendment, Amegy Bank (i) waived the Company’s events of default under the RLOC, (ii) reduced the aggregate limit of the RLOC to $2,750,000, (iii) reduced and limited the annual salary of the Company’s Chairman of the Board and President, Mr. Brooks, to not exceed $550,000, (iv) amended the financial covenants to state that the Company will not permit EBITDA to be less than $600,000 for the fiscal quarter ending December 31, 2019 and $125,000 for the fiscal quarter ending March 31, 2020, (v) extended the termination date of the RLOC to May 4, 2020, and (vi) provided for our Chairman of the Board and President to personally guarantee one hundred percent (100%) of the outstanding RLOC amount. On May 21, 2020, the Company executed the Fifth Amendment to the RLOC with Amegy Bank (the “Fifth Amendment”). Pursuant to the Fifth Amendment, Amegy Bank (i) waived the Company’s events of default under the RLOC, (ii) amended the financial covenants to state that the Company will not permit EBITDA to be less than $25,000 for the six months ended September 30, 2020, and (iii) extended the termination date of the RLOC until November 4, 2020. In conjunction with executing the Fifth Amendment to the RLOC, the Company obtained an additional $200,000 in capital in the form of subordinated debt from affiliates of Messrs. Brooks and Reeg. Specifically, on May 6, 2020, the Company borrowed $180,000 from NC 143 Family Holdings, LP, (“NC 143”), and $20,000 from Reeg Medical Industries (“RMI”), in exchange for two promissory notes which are unsecured and bear interest at 0.25% per annum until May 6, 2022, (subsequently extended to May 6, 2023), the maturity date, and 10.0% per annum after the maturity date, if not paid in full. Principal and interest are due and payable on the maturity date, provided, however, any payment of principal and interest on the loans is subordinated to payment of all indebtedness under the RLOC. On November 12, 2020, the Company executed a Sixth Amendment to the RLOC with Amegy Bank (the “Sixth Amendment”), which extended the termination date of our RLOC to May 4, 2021. On May 4, 2021, the Company executed a Seventh Amendment to the RLOC with Amegy Bank (the “Seventh Amendment”), waiving the events of default for the three months ended March 31, 2021 and extending the termination date of the RLOC until November 4, 2021. On August 5, 2021, the Company received a waiver from Amegy Bank, waiving the events of default for the minimum quarterly EBITDA requirements for the twelve months ended June 30, 2021. The Company was not in compliance with the minimum quarterly EBITDA requirement for the twelve months ended September 30, 2021. On November 4, 2021, the Company executed the Eighth Amendment, to the RLOC with Amegy bank. Pursuant to the Eighth Amendment, Amegy Bank (i) waived the events of default for the Company not meeting the minimum quarterly EBITDA for the twelve months ended September 30, 2021, (ii) reduced the aggregate limit of the loans offered pursuant to the Loan Agreement to $2,550,000, and (iii) extended the termination date of the loan to February 4, 2022. On December 14, 2021, the Company entered into the Credit Agreement with CNH Finance Fund I, L.P., a Delaware limited partnership (the “Lender”). The Credit Agreement provides for a secured revolving credit facility maturing on January 1, 2025 (the “Facility”) with an initial maximum principal in the amount of $5,000,000. Borrowings under the Facility are subject to a borrowing base as set forth in the Credit Agreement. The Company used borrowings under the Facility to repay in full (i) the Amended and Restated Business Loan Agreement, dated December 31, 2017, among ZB, N.A. (d/b/a Amegy Bank) and the Company and CPM (the “ Borrowers ”), as amended, and (ii) the U.S. Small Business Administration Loan Authorization and Agreement, dated May 12, 2020, between the Company and the U.S. Small Business Association, as amended. Borrowings under the Credit Agreement may be used for payment of fees, costs and expenses incurred in connection with the Credit Agreement and working capital for the Borrowers and their subsidiaries. Borrowings under the Credit Agreement bear interest at a floating rate, which will be at the Prime Rate plus 1.75%. Under the Credit Agreement, certain fees are payable by the Borrowers as set forth in the Credit Agreement. The obligations of the Borrowers with respect to the Credit Agreement are secured by a pledge of substantially all of the personal property assets of the Borrowers, including accounts receivables, deposit accounts, intellectual property, investment property, inventory, equipment and equity interests in their respective subsidiaries. The Credit Agreement contains customary affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay subordinated indebtedness and enter into affiliate transactions. In addition, the Credit Agreement contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of each calendar month (i) a current ratio of not less than 1.0 to 1.0, (ii) a fixed charge coverage ratio of not less than 1.0 to 1.0, (iii) a loan turnover rate of not greater than 60, and (iv) minimum liquidity of not less than $175,000, provided that if the Borrowers comply with the fixed charge coverage ratio for twelve consecutive months, the minimum liquidity covenant shall cease to be effective. The Credit Agreement also includes events of default customary for facilities of this type and upon the occurrence of any such event of default, all outstanding loans under the Facility may be accelerated and/or the lenders’ commitments terminated. The Credit Agreement contains customary representations and warranties of the Borrowers. These representations and warranties have been made solely for the benefit of the lender and such representations and warranties should not be relied on by any other person, including investors. In addition, such representations and warranties (i) have been qualified by disclosures made to the lenders in connection with the agreement, (ii) are subject to the materiality standards contained in the agreement which may differ from what may be viewed as material by investors and (iii) were made only as of the date of the agreement or such other date as is specified in the Credit Agreement. The foregoing description does not constitute a complete summary of the terms of the Credit Agreement and is qualified in its entirety by reference to the full text of the Credit Agreement, which is filed as Exhibit 10.45 to our 2021 Annual Report. Pursuant to the Credit Agreement, the Company had an outstanding balance of $2,240,171 as of June 30, 2022 and had reached the borrowing limit based on the Company’s borrowing base limitations. In preparation of the Credit Agreement, the Company incurred $240,858 of costs that have been allocated to intangible assets and will be amortized over the life of the Credit Agreement. Interest expense incurred on the Credit Agreement was $55,845 for the year ended June 30, 2022 and is reflected in interest expense on the Company’s accompanying consolidated statements of operations. Accrued interest on the Credit Agreement as of June 30, 2022 was $11,062, and is reflected in accrued expenses on the Company’s accompanying consolidated balance sheets. At June 30, 2022, the effective interest rate was 5.46%.

Notes Payable - Related Parties

Notes Payable - Related Parties	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable - Related Parties	Note 6. Notes Payable – Related Parties During July 2016 through October 2016, the Company obtained three working capital loans from NC 143 and RMI in the aggregate amount of $150,000 in exchange for convertible promissory notes (the “Notes”) bearing ten percent (10%) interest per annum until December 31, 2016, the maturity date, and eighteen percent (18%) interest per annum for periods subsequent to the maturity date. The Notes remain outstanding and principal and interest are due and payable, upon demand of the payee and at the holder’s sole discretion. The Notes’ holders have the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s Common Stock at a conversion price of $0.08 per share. On May 6, 2020, the Company borrowed $180,000 from NC 143 and $20,000 from RMI, in exchange for two promissory notes which are unsecured, and bear interest at 0.25% per annum until May 6, 2022, the maturity date, and 10.0% per annum after the maturity date, if not paid in full. Principal and interest are due and payable on the maturity date, provided, however, any payment of principal and interest on the loans is subordinated to payment of all indebtedness under the Credit Agreement. On March 25, 2022, the two promissory notes were amended to extend the maturity date from May 6, 2022, to May 6, 2023 During the three months ended June 30, 2022 and 2021, interest expense of $6,857 and $ 6,857, respectively, is reflected in interest expense on the Company’s accompanying interim unaudited condensed consolidated statements of operations. During the six months ended June 30, 2022 and 2021, interest expense of $13,640 and $13,639, respectively, is reflected in interest expense on the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022, and December 31, 2021 , accrued interest was $ 154,644 and $ 141,004 , respectively, which is reflected in accrued expenses on the Company’s accompanying interim unaudited condensed consolidated balance sheets.

Payroll Protection Program

Payroll Protection Program	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Payroll Protection Program	On April 11, 2020, the Company received approval from the U.S. Small Business Administration (“SBA”) to fund the Company’s request for a loan under the Payroll Protection Program (“PPP Loan”) created as part of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the SBA. In connection with the PPP Loan, the Company entered into a promissory note in the principal amount of $361,400. In accordance with the requirements of the CARES Act, the Company used the proceeds from the PPP Loan primarily for payroll costs. The PPP Loan was scheduled to mature on April 11, 2022, had a 1.00% interest rate, and was subject to the terms and conditions applicable to all loans made pursuant to the PPP. The Company applied for and received forgiveness for the total amount of the PPP Loan during the second quarter of 2021

Economic Injury Disaster Loan

Economic Injury Disaster Loan	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Economic Injury Disaster Loan	N ote 8 – Economic Injury Disaster Loan On May 12, 2020, the Company executed the standard loan documents (“SBA Loan Agreement”) required for securing a loan from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business (the “EIDL Loan”). Pursuant to the SBA Loan Agreement, the principal amount of the EIDL Loan was $150,000, with proceeds to be used for working capital purposes. Interest accrued at the rate of 3.75% per annum. Installment payments, including principal and interest, were due monthly beginning May 12, 2021 (twelve months from the date of the SBA Loan Agreement) in the amount of $731. The balance of principal and interest was payable thirty years from the date of the SBA Loan Agreement. EIDL Loan interest expense incurred for the three months ended June 30, 2022 and 2021 was approximately zero and $1,460, respectively, and is reflected in interest expense on the Company’s accompanying interim unaudited condensed consolidated statements of operations. EIDL Loan interest expense incurred for the six months ended June 30, 2022 and 2021 was approximately zero and $2,906, respectively, and is reflected in interest expense on the Company’s accompanying interim unaudited condensed consolidated statements of operations. On September 24, 2021, the Company executed the standard loan documents with the SBA for an amended and restated loan and authorization and agreement (“A&R SBA Loan Agreement”) required for securing an increase in the Company’s Original Note from the SBA EIDL Loan. Pursuant to the A&R SBA Loan Agreement, the principal amount for the EIDL Loan was increased by $350,000 to $500,000. Interest accrued at the rate of 3.75% per annum. The Company used borrowings under the Credit Agreement, as discussed in Note 5, to repay in full (i) the Amended and Restated Business Loan Agreement, dated December 31, 2017, among ZB, N.A. (d/b/a Amegy Bank) and the Borrowers as amended, and (ii) EIDL Loan.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders Equity Deficit [Abstract]
Stockholders' Equity	Note 9. Stockholders’ Equity Stock-Based Compensation The 2018 Amended and Restated Equity Incentive Plan of Fuse Medical, Inc. (“2018 Equity Plan”) is the Company’s stock-based compensation plan, which the Company’s Board of Directors (the “Board”) adopted on April 5, 2017, and subsequently amended and restated on December 13, 2018. The 2018 Equity Plan provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards, and restricted stock awards to employees, directors, consultants, and advisors. Awards granted pursuant to the 2018 Equity Plan are subject to a vesting schedule set forth in individual agreements. The Company estimates the fair value of stock-based compensation utilizing the Black-Scholes option pricing model. Black-Scholes option pricing is calculated using several variables, including the expected option term, expected volatility of the Company’s stock price over the expected option term, expected risk-free interest rate over the expected option term, expected dividend yield rate over the expected option term, and an estimate of expected forfeiture rates. The Company believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors, which are subject to ASC Topic 718 requirements. The Company estimates of fair value may not be reflective of actual future values or amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award. The Company utilizes the simplified method to estimate the expected life for stock options granted to employees, as the Company does not have sufficient historical data regarding stock option exercises. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased. The Company made an accounting policy election to account for forfeitures when they occur, versus estimating the number of awards that are expected to vest, in accordance with ASU 2016-09. Non-Qualified Stock Option Awards The Board did not grant any non-qualified stock option awards (“NQSOs”) for the three and six months ended June 30, 2022, and 2021. For the three months ended June 30, 2022 and 2021 the Company amortized $4,102 and $70,075, respectively, relating to the vesting of stock options which is included in selling, general, administrative, and other expenses on the Company’s accompanying interim unaudited condensed consolidated statements of operations. For the six months ended June 30, 2022 and June 30, 2021 the Company amortized $16,946 and $186,023, respectively, relating to the vesting of stock options which is included in selling, general, administrative, and other expenses on the Company’s accompanying interim unaudited condensed consolidated statements of operations. The Company will recognize $5,906 as an expense in future periods as the stock options vest. The Company recognizes stock compensation expense on a straight-line basis over the requisite service period for each award, which are subject to a vesting schedule as set forth in individual agreements. A summary of the Company’s stock option activity for the six months ended June 30, 2022, is presented below: No. of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance outstanding at December 31, 2021 1,745,000 $ 0.86 6.73 $ 12,000 Granted - - - - Exercised - - - - Forfeited - - - - Expired - - - - Balance outstanding at June 30, 2022 1,745,000 $ 0.86 6.24 $ - Exercisable at June 30, 2022 1,695,000 $ 0.87 6.21 $ - Restricted Common Stock The non-vested restricted stock awards (“RSAs”), as of June 30, 2022, were granted to the Company’s Board members as compensation. These awards vest only upon: (i) the occurrence of one of the Accelerating Events: (a) a Change in Control (as defined in an RSA Agreement); or (b) listing of the Company’s Common Stock on either NYSE or NASDAQ Stock Market; and (ii) the director’s delivery to the Company a Notice of Acceleration of Vesting (as defined in an RSA Agreement), within the Acceleration Notice Period (as defined in an RSA Agreement). As of June 30, 2022, and 2021, it was not probable that the performance conditions on the outstanding RSAs would be met, therefore, no expense has been recorded for these awards for the three and six months ended June 30, 2022 and 2021. There were no RSA’s that were granted, exercised, or forfeited during the six months ended June 30, 2022. Number of Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2021 2,574,227 $ 1,332,100 $ 0.52 Granted - - - Vested - - - Forfeited - - - Non-vested, June 30, 2022 2,574,227 $ 1,332,100 $ 0.52

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. Income Taxes The Company is subject to U.S. federal income taxes, in addition to state and local income taxes. The components of income tax expense are as follows: For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Current: Federal $ - $ - State 10,027 9,186 10,027 9,186 Deferred: Federal - - State - - - - Total income tax expense (benefit) $ 10,027 $ 9,186 Significant components of the Company's deferred income tax assets and liabilities are as follows: June 30, 2022 December 31, 2021 Deferred tax assets: Net operating loss carryover $ 1,439,042 $ 1,262,269 Accounts receivable 83,090 104,635 Compensation 559,495 555,936 Inventory 454,371 523,131 Other 20,019 1,244 Total deferred tax assets 2,556,017 2,447,215 Deferred tax liabilities: Intangibles (194,809 ) (198,801 ) Property and equipment (19,481 ) (1,522 ) Total deferred tax liabilities (214,290 ) (200,323 ) Deferred tax assets, net $ 2,341,727 $ 2,246,892 Valuation allowance: Beginning of year (2,246,892 ) (1,816,546 ) Increase during the year (94,835 ) (430,346 ) Ending balance (2,341,727 ) (2,246,892 ) Net deferred tax asset $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company recorded a valuation allowance totaling $94,835 for the six months ended June 30,2022 due to the uncertainty of realization. Management believes that based upon the history of losses that the Company has incurred to date and its projection of future taxable operating income for the foreseeable future, it is more likely than not that the Company will not be able to realize the tax benefit associated with deferred tax assets. The valuation allowance established as of June 30, 2022 was $2,341,727. At June 30, 2022, the Company estimates it has approximately $6,852,583 of net operating loss carryforwards which $1,741,108 will expire during 2022 through 2038. Under Section 382 of the Internal Revenue Code of 1986, as amended ("IRC Section 382"), a corporation that undergoes an "ownership change", as defined therein, is subject to limitation on its use of pre-change tax attributes carryforward to offset future taxable income. The Company completed a 382 study and determined that there were changes in ownership in prior years which limited the NOL from 2013 and earlier, and 2014 through 2016. The 382 limitation mathematically precludes the use of approximately $2,122,191 of net operating loss carryforwards, therefore, the deferred net operating loss carryover asset excludes the portion of net operating loss that are mathematically excluded from future use by the Company. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for unrecognized tax positions. As of June 30, 2022, all the tax years remained open to examination for three years from the tax year in which net operating losses are utilized. The Company was not subject to examination by any income taxing authority as of June 30, 2022. A reconciliation of income tax computed at the U.S. statutory rate to the effective income tax rate is as follows: Six Months Ended June 30, 2022 June 30, 2021 Expected U.S. federal incomes as statutory rate 21.0% 21.0% Gain on Payroll Protection Loan 0.0% 14.5% Permanent differences 0.0% 0.0% State and local income taxes, net of federal benefit -1.8% -1.4% Change in deferred tax asset valuation allowance -21.5% -35.9% Effective tax rate -2.3% -1.8% Our effective income tax rates for the six months ended June 30, 2022 and June 30, 2021 were -2.3% and -1.8%, respectively. This decrease from prior period is driven by the valuation allowance allocated to the deferred tax asset for the current period.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2022
Nature Of Operations And Going Concern [Abstract]
Concentrations	Note 11. Concentrations Concentration of Revenues, Accounts Receivable and Suppliers For the six months ended June 30, 2022 and 2021, the following significant customers had an individual percentage of total revenues equaling ten percent (10%) or greater: For the Six Months Ended June 30, 2022 June 30, 2021 Customer 1 11.24 % 0.12 % Customer 2 1.78 % 17.05 % Totals 13.02 % 17.17 % At June 30, 2022 and December 31, 2021, there was one and two significant customers, respectively, that had a concentration of accounts receivable representing ten percent (10%) or greater of accounts receivable: June 30, 2022 December 31, 2021 Customer 1 13.65 % 1.84 % Customer 2 4.53 % 13.46 % Customer 3 3.72 % 11.21 % Totals 21.90 % 26.51 % For the six months ended June 30, 2022 and 2021, the following significant suppliers represented ten percent (10%) or greater of goods purchased: For the Six Months Ended June 30, 2022 June 30, 2021 Supplier 1 20.64 % 21.90 % Supplier 2 11.07 % 12.00 % Totals 31.71 % 33.90 %

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. Related Party Transactions Lease with 1565 North Central Expressway, LP For its principal executive office, the Company leases an aggregate of approximately 11,500 square-foot space at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080 from 1565 North Central Expressway, LP (“NCE, LP”), a real estate investment company that is owned and controlled by Mr. Brooks. The Company’s lease arrangement includes (i) the lease acquired pursuant to the CPM Acquisition effective January 1, 2013, and (ii) a lease effective July 14, 2017 entered into to support the Company’s relocation of its Fort Worth, Texas corporate offices to CPM’s executive offices. Both leases terminated December 31, 2017, with month-to-month renewals thereafter. For the six months ended June 30, 2022 and 2021, the Company paid approximately $84,000 and $84,000, respectively, in rent expense, which is reflected in selling, general, administrative, and other expenses in the Company’s accompanying interim unaudited condensed consolidated statements of operations. AmBio Contract The Company engaged AmBio Staffing, LLC (“AmBio”), a Texas licensed Professional Employment Organization, to provide payroll processing, employee benefit administration, and related human capital services effective January 1, 2017. Mr. Brooks owns and controls AmBio. As of June 30, 2022, AmBio operations support approximately 39 full time equivalents (“FTE”). Of those 39 FTEs, 35 FTEs directly support the Company, and 3 FTEs support the operations of other companies, and 1 FTE is shared between the Company and other companies. As of June 30, 2022 and December 31, 2021, the Company owed amounts to AmBio of approximately $157,991 and $170,784, respectively, which are reflected in accounts payable on the Company’s accompanying interim unaudited condensed consolidated balance sheets. For the six months ended June 30, 2022 and June 30, 2021, the Company paid approximately $97,546 and $93,000, respectively, to AmBio in administrative fees, which are reflected in selling, general, administrative, and other expenses in the Company’s accompanying interim unaudited condensed consolidated statements of operations. Operations Historically, the Company conducts various related-party transactions with entities that are owned by or affiliated with Mr. Brooks and Mr. Reeg. These transactions are based on wholesale contractual agreements that the Company believes are on terms and conditions substantially similar to other third-party contractual agreements. As described more fully below, these transactions include: selling and purchasing of inventory on a wholesale basis, commissions earned and paid and shared-service fee arrangements. MedUSA Group, LLC MedUSA Group, LLC (“MedUSA”) is a sub-distributor owned and controlled by Mr. Brooks and Mr. Reeg. During the six months ended June 30, 2022 and 2021, the Company: • sold Orthopedic Implants and Biologics products to MedUSA in the amounts of approximately zero and $1,400, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations; and • incurred approximately $1,698,152 and $1,718,298, respectively, in commission costs, which are reflected in commissions in the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022 and December 31, 2021, the Company had approximately $1,671,431 and $923,960, respectively, of unpaid commission costs due to MedUSA, which is reflected in accrued liabilities in the Company’s accompanying interim unaudited condensed consolidated balance sheets. As of June 30, 2022 and December 31, 2021, the Company had outstanding balances due from MedUSA of approximately zero and $63,498, respectively. These amounts are reflected in accounts receivable, net of allowance, in the Company’s accompanying interim unaudited condensed consolidated balance sheets. Payment terms per our stocking and distribution agreement with MedUSA are 30 days from receipt of invoice. As of June 30, 2022, MedUSA had no past due balance. Texas Overlord, LLC Texas Overlord, LLC (“Overlord”) is an investment holding-company owned and controlled by Mr. Brooks. During the six months ended June 30, 2022 and 2021, the Company: • incurred approximately $75,000 and $120,000, respectively, in commission costs, which are reflected in commissions in the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022 and December 31, 2021, the Company had approximately $115,000 and $40,000 of unpaid commission costs owed to Overlord, which are reflected in accrued liabilities in the Company’s accompanying interim unaudited condensed consolidated balance sheets. As of June 30, 2022, the Company had approximately $54,073 of unpaid liabilities related to payments made on behalf of the Company by Overlord to settle accounts payable, which are reflected in accrued liabilities in the Company’s accompanying interim unaudited condensed consolidated balance sheets. As of June 30, 2022 and December 31, 2021, the Company had no outstanding balances due from Overlord. NBMJ, Inc. NBMJ, Inc. d/b/a Incare Technology (“NBMJ”) is a durable medical equipment, wound care, and surgical supplies distributor owned and controlled by Mr. Brooks. During the six months ended June 30, 2022 and 2021, the Company sold Biologics products to NBMJ in the amounts of approximately $350 and $71,381, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022 and December 31, 2021, the Company had $2,430 and $2,080 in outstanding balances due from NBMJ. These amounts are reflected in accounts receivable, net of allowance, in the Company’s accompanying interim unaudited condensed consolidated balance sheets. Payment terms per the stocking and distribution agreement with NBMJ are 30 days from receipt of invoice. As of June 30, 2022, NBMJ had a past due balance of $2,430. Bass Bone and Spine Specialists Bass Bone & Spine Specialists (“Bass”) operates as a sub-distributor of surgical implants and is owned and controlled by Mr. Brooks. During the six months ended June 30, 2022 and 2021, the Company: • sold Orthopedic Implants and Biologics products to Bass in the amounts of approximately $19,985 and $23,227, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022 and December 31, 2021, the Company had outstanding balances due from Bass of approximately $15,148 and $8,413, respectively. These amounts are reflected in accounts receivable, net of allowance, in the Company’s accompanying interim unaudited condensed consolidated balance sheets. Payment terms per the stocking and distribution agreement with Bass are 30 days from receipt of invoice. As of June 30, 2022, Bass had a past due balance of $13,298. Sintu, LLC Sintu, LLC (“Sintu”) operates as a sub-distributor of surgical implants and is owned and controlled by Mr. Brooks. During the six months ended June 30, 2022 and 2021, the Company incurred approximately $253,969 and $209,089, respectively, in commission costs to Sintu, which are reflected in commissions on the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022, and December 31, 2021, the Company had approximately $811,197 and $557,228, respectively, of unpaid commission costs due to Sintu, which is reflected in accrued liabilities in the Company’s accompanying interim unaudited condensed consolidated balance sheets. Tiger Orthopedics, LLC Tiger Orthopedics, LLC (“Tiger”) operates as a sub-distributor of surgical implants and is owned and controlled by Mr. Brooks. During the six months ended June 30, 2022 and June 30, 2021, the Company sold Orthopedic Implants and Biologics products to Tiger in the amounts of approximately zero and $502, respectively, which are reflected in net revenues in the Company’s accompanying interim unaudited condensed consolidated statements of operations. As of June 30, 2022 and December 31, 2021, the Company had no outstanding balances due from Tiger. Payment terms per the stocking and distribution agreement with Tiger are 30 days from receipt of invoice. As of June 30, 2022, Tiger had no past due balance. Modal Manufacturing, LLC Modal Manufacturing, LLC (“Modal”) is a manufacturer of medical devices owned and controlled by Mr. Brooks. During the six months ended June 30, 2022 and 2021, the Company purchased approximately $343,713 and $368,443, respectively, in Orthopedic Implants and medical instruments from Modal, which are reflected within inventories, net of allowance in the Company’s accompanying interim unaudited condensed consolidated balance sheets. As of June 30, 2022 and December 31, 2021, the Company had outstanding balances owed to Modal of approximately $877,789 and $709,234, respectively. These amounts are reflected in accounts payable in the Company’s accompanying interim unaudited condensed consolidated balance sheets. Payment terms per the stocking and distribution agreement with Modal are 30 days from receipt of invoice. As of June 30, 2022, the Company had a past due balance of approximately $848,443 owed to Modal.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The interim unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, CPM. Intercompany transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the interim unaudited condensed consolidated financial statements in accordance with GAAP, requires the Company to make estimates and assumptions that affect the Company’s reported amounts in the interim unaudited condensed consolidated financial statements. Actual results could differ from those estimates. Significant estimates on the accompanying interim unaudited condensed consolidated financial statements include the allowance for doubtful accounts, valuation of inventories, the Company’s effective income tax rate, the fair value calculations of stock-based compensation, goodwill, finite lived intangibles and the earn-out (“Earn-Out”) liability.
Segment Reporting	Segment Reporting In accordance with Accounting Standards Codification (“ASC”) No. 280, “ Segment Reporting
Reclassifications	Reclassification Medical instrument depreciation was previously reported as a component of cost of revenues in the Company’s accompanying consolidated statements of operations. Medical instruments are orthopedic devices that are utilized in all cases where our Orthopedic Implants are implanted. Subsequent to December 31, 2021, the Company began depreciating these medical instruments over 3 years and have now reclassed this depreciation expense to depreciation and amortization in the accompanying consolidated statements of operations.
Loss Per Common Share	Loss Per Common Share Loss per common share, basic is calculated by dividing the net income/(loss) attributable to common stockholders by the weighted-average number of common stock, par value $0.01 (“Common Stock”), outstanding during the period, without consideration of Common Stock equivalents. Shares of restricted stock are included in the basic weighted-average number of Common Stock outstanding from the time they vest. Diluted loss per common share is computed by dividing net income/(loss) by the weighted-average number of Common Stock equivalents outstanding for the period determined using the treasury stock method. For the six months ended June 30, 2022 and 2021, the Company excluded the effects of outstanding stock options, convertible notes and, to the extent vested, restricted stock as their effects were antidilutive due to the Company’s operating loss during these periods. (See Note 9, “Stockholders’ Equity” for the terms and conditions of restricted stock).
Fair Value Measurements	Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets; Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. In connection with the CPM Acquisition, the Company initially recorded a $19,244,543 liability related to the Earn-Out portion of the purchase consideration. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability is evaluated each reporting period and changes in its fair value are included in the Company’s earnings. The Earn-Out payments are based on the financial performance of the Company between the period of January 1, 2018 , and December 31, 2034 . The base amount of the Earn-Out is up to $ 16,000,000 with an additional bonus payment up to $ 10,000,000 . The payments of the base and bonus Earn-Out amounts are subject to the Company meeting certain earnings thresholds as detailed in the CPM Acquisition Agreement. The Earn-Out liability, which represents contingent consideration associated with the CPM Acquisition, is recorded as a liability. This liability is subject to re-measurement to fair value at each reporting date until the contingency is resolved and the changes in fair value are recognized in the consolidated statements of operations at each reporting period. The Earn-Out was remeasured to fair value under the probability weighted income approach. As a result, the fair value of the Earn-Out liability was reduced by $342,168 from $11,936,000 to $11,593,832 in 2021 and increased by $290,635 from $11,645,365 to $11,936,000 in 2020 and reflected as “Change in fair value of contingent purchase consideration” on our Consolidated Financial Statements. There was no change in the Earn-Out liability for the six months ended June 30, 2022 and there were no significant changes in the Level 3 inputs from those utilized at December 31, 2021. The required earnings thresholds have not been met from inception of the agreements through June 30, 2022, and as such, there have been no payments required for either the base or bonus Earn-Out tranches.
Financial Instruments	Financial Instruments The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded values of notes payable approximate their respective fair values based upon their effective interest rates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at June 30, 2022 and December 31, 2021. The Company’s cash is concentrated in one large financial institution. The amount of cash held at the financial institution may at times exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any financial institution losses from inception through June 30, 2022. As of June 30, 2022 and December 31, 2021, there were deposits of $523,993 and $594,536 , respectively,
Accounts Receivable and Allowances	Accounts Receivable and Allowances Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable and an allowance for contractual discount pricing. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other factors considered by the Company. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery. The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstances warrant, the Company estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying interim unaudited condensed consolidated statements of operations. When accounts are deemed uncollectible, they are often referred to the Company’s outside legal firm for litigation. Accounts deemed uncollectible are written-off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. Accounts deemed uncollectible are removed from the Company’s accounts receivable portfolio, with a corresponding offset to the allowance for doubtful accounts receivable. The Company may record additional allowances for doubtful accounts based on known trends and expectations to ensure the Company’s accounts receivable portfolio is recorded at net realizable value. Specific allowances are re-evaluated and adjusted as additional facts and information become available. Previously written-off accounts receivable subsequently collected are recognized as a reduction of bad debt expense when funds are received. The Company estimates its allowance for contractual discount pricing, by evaluating specific accounts where information indicates the customer is offered contractual pricing and discount allowances. In these arrangements, the Company uses assumptions and judgement, based on the best available facts and circumstances to record a specific allowance for the amounts due from those customers. The allowance is offset by a corresponding reduction to revenue. These specific allowances are re-evaluated, analyzed, and adjusted as additional information becomes available to determine the total amount of the allowance. The Company may record additional allowances based on trends and expectations to ensure the Company’s accounts receivable portfolio is recorded at net realizable value.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value (first-in, first-out) which includes an allowance for slow-moving inventory, expired inventory, and inventory obsolescence. Inventories consist entirely of finished goods and include internal and external fixation products; upper and lower extremity plating and total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, “Orthopedic Implants”) and osteo-biologics and regenerative tissue which include human allografts, substitute bone materials, tendons, as well as amniotic tissues (collectively, “Biologics”). The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. In cases where the market values are less than the carrying value, a write-down is recognized equal to an amount by which the carrying value exceeds the market value of inventories.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets per the following table. Expenditures for additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. The Company reviews long-lived assets for impairment annually or whenever changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Category Useful Life Computer equipment and software 3 years Furniture and fixtures 3 years Office equipment 3 years Medical instruments 3 years Software 3 years Upon the retirement or disposition of property and equipment, the related cost and accumulated depreciation is removed. A gain is recorded when consideration received is more than the disposed asset’s cost, net of depreciation, and a loss is recorded when consideration received is less than the disposed asset’s cost, net of depreciation.
Long-Lived Assets	Long-Lived Assets The Company reviews other long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows, which is at the individual asset level or the asset group level. The undiscounted cash flows expected to be generated by the related assets are estimated over their useful life based on updated projections. If the evaluation indicates that the carrying amount of the assets may not be recoverable, any potential impairment is measured based upon the fair value of the related assets or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale, if any, are recorded at the lower of carrying amount or fair value less costs to sell.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill is determined based on an acquisition purchase price in excess of the fair value of identified net assets acquired. Intangible assets with lives restricted by contractual, legal, or other means are amortized over their useful lives. Goodwill is not amortized, but is tested in the fourth quarter each year for impairment, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. The Company performs its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. ASC 350-30-35-18, “ Intangible assets not subject to amortization The Company’s intangible assets subject to amortization consist primarily of acquired non-compete agreements, funds to secure Credit and Security Agreement (the “Credit Agreement”) with CNH Finance Fund I, L.P., and customer relationships. Amortization expense is calculated using the straight-line method over the asset’s expected useful life.
Revenue Recognition	Revenue Recognition The Company’s revenues are generated from the sales of Orthopedic Implants and Biologics to support orthopedic surgeries. The Company obtains purchase orders from its customers for the sale of its products which sets forth the general terms and conditions including line item pricing and payment terms (generally due upon receipt). The Company recognizes revenue when its customers obtain control over the assets (generally when the title passes upon shipment or when a product is utilized in a surgery), and it is probable that the Company will collect substantially all the amounts due. Individual promised goods are the Company’s only performance obligation. Due to the nature of its products, the Company’s product returns have been historically immaterial. The Company includes shipping and handling fees in net revenues. Shipping and handling costs are associated with outbound freight after control over a product has transferred to a customer and are accounted for as a fulfillment cost and are included in cost of goods sold on the Company’s accompanying interim unaudited condensed consolidated statements of operations. Revenue Differentiation The Company measures sales volume based on medical procedures in which the Company’s products are sold and used (“Cases”). The Company considers Cases resulting from direct sales to medical facilities to be retail cases (“Retail Cases”) and Cases resulting from sales to third parties, such as non-medical facilities, distributors, or sub-distributors, to be wholesale cases (“Wholesale Cases”). Some of the Company’s sales for Wholesale Cases are on a consignment basis with a third party. When consigned, the revenue is not recorded until the device is implanted in a patient during surgery. In the Company’s industry, Retail Cases are typically sold at higher price points than Wholesale Cases, resulting in greater revenue and gross profit per Case. Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Category Retail $ 4,500,975 $ 5,159,510 $ 8,794,731 $ 9,143,388 Wholesale 167,315 505,505 427,897 962,386 Total $ 4,668,290 $ 5,665,015 $ 9,222,628 $ 10,105,774
Cost of Revenues	Cost of Revenues Cost of revenues consists of (i) cost of goods sold, (ii) freight and shipping costs for items sold to customers, (iii) cost of storage, (iv) inventory shrink, and (v) an estimate for slow-moving inventory, expired inventory, and inventory obsolescence.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors, and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro-rata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued, both effective and not yet effective. Other recent accounting pronouncements issued by the Financial Accounting Standards Board, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by the Company to have a material impact on the Company's present or future consolidated financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Estimated Useful Lives of Assets	Category Useful Life Computer equipment and software 3 years Furniture and fixtures 3 years Office equipment 3 years Medical instruments 3 years Software 3 years
Schedule of Revenue Differentiation	The Company measures sales volume based on medical procedures in which the Company’s products are sold and used (“Cases”). The Company considers Cases resulting from direct sales to medical facilities to be retail cases (“Retail Cases”) and Cases resulting from sales to third parties, such as non-medical facilities, distributors, or sub-distributors, to be wholesale cases (“Wholesale Cases”). Some of the Company’s sales for Wholesale Cases are on a consignment basis with a third party. When consigned, the revenue is not recorded until the device is implanted in a patient during surgery. In the Company’s industry, Retail Cases are typically sold at higher price points than Wholesale Cases, resulting in greater revenue and gross profit per Case. Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Category Retail $ 4,500,975 $ 5,159,510 $ 8,794,731 $ 9,143,388 Wholesale 167,315 505,505 427,897 962,386 Total $ 4,668,290 $ 5,665,015 $ 9,222,628 $ 10,105,774

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following at June 30, 2022 and December 31, 2021: June 30, 2022 December 31, 2021 Computer equipment and software $ 20,249 $ 20,249 Medical instruments 422,973 - Office equipment - - Property and equipment costs 443,222 20,249 Less: accumulated depreciation (91,611 ) (12,998 ) Property and equipment, net $ 351,611 $ 7,251

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill and Other Intangible Assets	The following table summarizes the Company’s goodwill and other intangible assets: June 30, 2022 December 31, 2021 Amortization period (years) Intangible assets: 510(k) product technology $ 704,380 $ 704,380 Indefinite Customer relationships 555,819 555,819 11 CNH Credit Agreement 240,858 236,358 3 Total intangible assets 1,501,057 1,496,557 Less: accumulated amortization (244,647 ) (179,216 ) Intangible assets, net 1,256,410 1,317,341 Goodwill $ 1,972,886 $ 1,972,886 Indefinite

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders Equity Deficit Tables [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity for the six months ended June 30, 2022, is presented below: No. of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance outstanding at December 31, 2021 1,745,000 $ 0.86 6.73 $ 12,000 Granted - - - - Exercised - - - - Forfeited - - - - Expired - - - - Balance outstanding at June 30, 2022 1,745,000 $ 0.86 6.24 $ - Exercisable at June 30, 2022 1,695,000 $ 0.87 6.21 $ -
Summary of Restricted Stock Awards Activity	There were no RSA’s that were granted, exercised, or forfeited during the six months ended June 30, 2022. Number of Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2021 2,574,227 $ 1,332,100 $ 0.52 Granted - - - Vested - - - Forfeited - - - Non-vested, June 30, 2022 2,574,227 $ 1,332,100 $ 0.52

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	The components of income tax expense are as follows: For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Current: Federal $ - $ - State 10,027 9,186 10,027 9,186 Deferred: Federal - - State - - - - Total income tax expense (benefit) $ 10,027 $ 9,186
Significant Components of Deferred Income Tax Assets and Liabilities	Significant components of the Company's deferred income tax assets and liabilities are as follows: June 30, 2022 December 31, 2021 Deferred tax assets: Net operating loss carryover $ 1,439,042 $ 1,262,269 Accounts receivable 83,090 104,635 Compensation 559,495 555,936 Inventory 454,371 523,131 Other 20,019 1,244 Total deferred tax assets 2,556,017 2,447,215 Deferred tax liabilities: Intangibles (194,809 ) (198,801 ) Property and equipment (19,481 ) (1,522 ) Total deferred tax liabilities (214,290 ) (200,323 ) Deferred tax assets, net $ 2,341,727 $ 2,246,892 Valuation allowance: Beginning of year (2,246,892 ) (1,816,546 ) Increase during the year (94,835 ) (430,346 ) Ending balance (2,341,727 ) (2,246,892 ) Net deferred tax asset $ - $ -
Reconciliation of Income Tax Computed at U.S. Statutory Rate to Effective Income Tax Rate	A reconciliation of income tax computed at the U.S. statutory rate to the effective income tax rate is as follows: Six Months Ended June 30, 2022 June 30, 2021 Expected U.S. federal incomes as statutory rate 21.0% 21.0% Gain on Payroll Protection Loan 0.0% 14.5% Permanent differences 0.0% 0.0% State and local income taxes, net of federal benefit -1.8% -1.4% Change in deferred tax asset valuation allowance -21.5% -35.9% Effective tax rate -2.3% -1.8%

Concentrations (Tables)

Concentrations (Tables)	6 Months Ended
	Jun. 30, 2022
Revenues [Member]
Concentration Risk [Line Items]
Concentration of Revenues, Accounts Receivable and Suppliers	For the six months ended June 30, 2022 and 2021, the following significant customers had an individual percentage of total revenues equaling ten percent (10%) or greater: For the Six Months Ended June 30, 2022 June 30, 2021 Customer 1 11.24 % 0.12 % Customer 2 1.78 % 17.05 % Totals 13.02 % 17.17 %
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration of Revenues, Accounts Receivable and Suppliers	At June 30, 2022 and December 31, 2021, there was one and two significant customers, respectively, that had a concentration of accounts receivable representing ten percent (10%) or greater of accounts receivable: June 30, 2022 December 31, 2021 Customer 1 13.65 % 1.84 % Customer 2 4.53 % 13.46 % Customer 3 3.72 % 11.21 % Totals 21.90 % 26.51 %
Goods Purchased [Member]
Concentration Risk [Line Items]
Concentration of Revenues, Accounts Receivable and Suppliers	For the six months ended June 30, 2022 and 2021, the following significant suppliers represented ten percent (10%) or greater of goods purchased: For the Six Months Ended June 30, 2022 June 30, 2021 Supplier 1 20.64 % 21.90 % Supplier 2 11.07 % 12.00 % Totals 31.71 % 33.90 %

Nature of Operations (Details N

Nature of Operations (Details Narrative)			6 Months Ended
	Aug. 01, 2018	Dec. 31, 2017	Jun. 30, 2022
CPM [Member]
Nature Of Operations And Going Concern [Line Items]
Acquisition agreement month and year		2017-12
Maxim Surgical, LLC [Member]
Nature Of Operations And Going Concern [Line Items]
Acquisition agreement month and year	2018-08
Date of termination agreement			Dec. 20, 2019

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) Segment $ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2017 USD ($)
Significant Accounting Policies [Line Items]
Number of operating segments | Segment	1
Number of reportable segments | Segment	1
Common stock, par value | $ / shares	$ 0.01	$ 0.01
Earn-out liability	$ 11,593,832	$ 11,593,832	$ 11,936,000	$ 11,645,365
Amount of earn-out liability increased/reduced		342,168	$ 290,635
Cash equivalents	0	0
FDIC insurance limit	250,000
Deposits greater than federally insured limit	$ 523,993	$ 594,536
CPM [Member]
Significant Accounting Policies [Line Items]
Earn-out payment start date	Jan. 01, 2018
Earn-out payment end date	Dec. 31, 2034
Earn-out liability	$ 0				$ 19,244,543
CPM [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Earn-out payment base amount	16,000,000
Earn-out payment additional bonus amount	$ 10,000,000

Significant Accounting Polici_5

Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	6 Months Ended
	Jun. 30, 2022
Computer Equipment and Software [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Office equipment [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Medical Instruments [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Software [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of Revenue Differentiation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Net revenues	$ 4,668,290	$ 5,665,015	$ 9,222,628	$ 10,105,774
Retail [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	4,500,975	5,159,510	8,794,731	9,143,388
Wholesale [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 167,315	$ 505,505	$ 427,897	$ 962,386

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment costs	$ 443,222	$ 20,249
Less: accumulated depreciation	(91,611)	(12,998)
Property and equipment, net	351,611	7,251
Computer Equipment and Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment costs	20,249	$ 20,249
Medical Instruments [Member]
Property Plant And Equipment [Line Items]
Property and equipment costs	$ 422,973

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Depreciation expense	$ 56,209	$ 2,832	$ 78,613	$ 6,992

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill and Other Intangible Assets (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Intangible assets:
Total intangible assets	$ 1,501,057	$ 1,496,557
Less: accumulated amortization	(244,647)	(179,216)
Intangible assets, net	1,256,410	1,317,341
Goodwill	1,972,886	1,972,886
510(k) Product Technology [Member]
Intangible assets:
Indefinite lived intangible assets	$ 704,380	704,380
Intangible assets, amortization period	Indefinite
Goodwill [Member]
Intangible assets:
Intangible assets, amortization period	Indefinite
Customer Relationships [Member]
Intangible assets:
Finite lived intangible assets	$ 555,819	555,819
Intangible assets, amortization period	11 years
C N H Credit Agreement
Intangible assets:
Finite lived intangible assets	$ 240,858	$ 236,358
Intangible assets, amortization period	3 years

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 32,715	$ 12,633	$ 65,431	$ 25,266

Senior Secured Revolving Cred_2

Senior Secured Revolving Credit Facility (Details Narrative) - USD ($)

3 Months Ended

6 Months Ended

Mar. 25, 2022

Dec. 14, 2021

Nov. 04, 2021

May 04, 2021

Nov. 12, 2020

May 21, 2020

May 06, 2020

Dec. 18, 2019

May 09, 2019

Nov. 19, 2018

Dec. 29, 2017

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2022

Sep. 30, 2020

RLOC [Member] | 0.25% Promissory Notes [Member]

Debt Instrument [Line Items]

Subordinated debt from affiliates

$ 200,000

Maturity date

May 06, 2023

May 06, 2022

May 06, 2023

Interest rate percentage

0.25%

Interest rate per annum after maturity date

10%

RLOC [Member] | 0.25% Promissory Notes [Member] | NC 143 [Member]

Debt Instrument [Line Items]

Borrowed from related parties

$ 180,000

RLOC [Member] | 0.25% Promissory Notes [Member] | RMI [Member]

Debt Instrument [Line Items]

Borrowed from related parties

$ 20,000

RLOC [Member] | Amegy Bank [Member] | Fifth Amendment [Member]

Debt Instrument [Line Items]

Line of credit facility, expiration date

Nov. 04, 2020

Description of financial covenants

the Company will not permit EBITDA to be less than $25,000 for the six months ended September 30, 2020

Minimum net profit required for compliance

$ 25,000

RLOC [Member] | Amegy Bank [Member] | Sixth Amendment [Member]

Debt Instrument [Line Items]

Line of credit facility, expiration date

May 04, 2021

RLOC [Member] | Amegy Bank [Member] | Seventh Amendment [Member]

Debt Instrument [Line Items]

Line of credit facility, expiration date

Nov. 04, 2021

RLOC [Member] | Amegy Bank [Member] | Eighth Amendment [Member]

Debt Instrument [Line Items]

Line of credit maximum borrowing capacity

$ 2,550,000

Line of credit facility, expiration date

Feb. 04, 2022

RLOC [Member] | CNH Finance Fund [Member] | Credit and Security Agreement [Member]

Debt Instrument [Line Items]

Line of credit maximum borrowing capacity

$ 5,000,000

Minimum fixed charge coverage ratio

1%

Description of financial covenants

the last day of each calendar month (i) a current ratio of not less than 1.0 to 1.0, (ii) a fixed charge coverage ratio of not less than 1.0 to 1.0, (iii) a loan turnover rate of not greater than 60, and (iv) minimum liquidity of not less than $175,000, provided that if the Borrowers comply with the fixed charge coverage ratio for twelve consecutive months, the minimum liquidity covenant shall cease to be effective.

Maturity date

Jan. 01, 2025

Minimum current ratio

1%

Minimum Liquidity Amount

$ 175,000

Line of credit outstanding balance amount

$ 2,240,171

Interest costs incurred

240,858

Interest expense

55,845

Accrued interest

$ 11,062

Effective interest rate

5.46%

RLOC [Member] | CNH Finance Fund [Member] | Credit and Security Agreement [Member] | Prime Rate [Member]

Debt Instrument [Line Items]

Interest rate

1.75

CPM [Member] | RLOC [Member] | Amegy Bank [Member]

Debt Instrument [Line Items]

Date of acquisition agreement

Dec. 29, 2017

Line of credit maximum borrowing capacity

$ 5,000,000

Percentage of guarantees of outstanding loan amount

50%

CPM [Member] | RLOC [Member] | Amegy Bank [Member] | First Amendment [Member]

Debt Instrument [Line Items]

Minimum net income to achieve

$ 700,000

CPM [Member] | RLOC [Member] | Amegy Bank [Member] | Second Amendment [Member]

Debt Instrument [Line Items]

Line of credit maximum borrowing capacity

$ 4,000,000

Line of credit facility, expiration date

Nov. 04, 2019

Variable rate, description

one-month LIBOR rate

Variable rate

4%

Minimum fixed charge coverage ratio

1.25%

Description of financial covenants

the Fixed Charge Coverage Ratio of any calendar quarter end from and after the quarter ending June 30, 2019, to be less than 1.25 to 1.00; EBITDA to be less than $700,000 for the fiscal quarter ending December 31, 2018, and $100,000 for the fiscal quarter ending March 31, 2019

Minimum net profit required for compliance

$ 100,000

$ 700,000

CPM [Member] | RLOC [Member] | Amegy Bank [Member] | Third Amendment [Member]

Debt Instrument [Line Items]

Line of credit maximum borrowing capacity

$ 3,500,000

Line of credit facility, expiration date

May 09, 2019

Description of financial covenants

amended the financial covenants to state that the Company will not permit EBITDA to be less than $100,000 for the fiscal quarter ending June 30, 2019 and $500,000 for the fiscal quarter ending September 30, 2019

Minimum net profit required for compliance

$ 500,000

$ 100,000

Line of credit component of inventory percentage

30%

CPM [Member] | RLOC [Member] | Amegy Bank [Member] | Fourth Amendment [Member]

Debt Instrument [Line Items]

Line of credit maximum borrowing capacity

$ 2,750,000

Percentage of guarantees of outstanding loan amount

100%

Line of credit facility, expiration date

May 04, 2020

Description of financial covenants

amended the financial covenants to state that the Company will not permit EBITDA to be less than $600,000 for the fiscal quarter ending December 31, 2019 and $125,000 for the fiscal quarter ending March 31, 2020

Minimum net profit required for compliance

$ 125,000

$ 600,000

CPM [Member] | RLOC [Member] | Amegy Bank [Member] | Fourth Amendment [Member] | Mr. Brooks [Member]

Debt Instrument [Line Items]

Maximum annual salary of chairman of board and president

$ 550,000

CPM [Member] | Credit Card Exposure [Member] | Amegy Bank [Member] | Third Amendment [Member]

Debt Instrument [Line Items]

Line of credit maximum borrowing capacity

$ 500,000

Notes Payable - Related Parti_2

Notes Payable - Related Parties (Details Narrative) - USD ($)			3 Months Ended		4 Months Ended	6 Months Ended		12 Months Ended
	Mar. 25, 2022	May 06, 2020	Jun. 30, 2022	Jun. 30, 2021	Oct. 31, 2016	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2017	Dec. 31, 2021
Debt Instrument [Line Items]
Interest expense on notes payable			$ 6,857	$ 6,857		$ 13,640	$ 13,639
Accrued expenses [Member]
Debt Instrument [Line Items]
Accrued interest			$ 154,644			$ 154,644			$ 141,004
10% Promissory Notes [Member] | NC 143 Family Holdings, LP and RMI [Member]
Debt Instrument [Line Items]
Convertible notes payable - related parties					$ 150,000
Interest rate of promissory notes					10%			18%
Debt Instrument, description						principal and interest balance into shares of the Company’s Common Stock at a conversion price of $0.08 per share.
Conversion price of common stock					$ 0.08
0.25% Promissory Notes [Member] | RLOC [Member]
Debt Instrument [Line Items]
Interest rate percentage		0.25%
Maturity date	May 06, 2023	May 06, 2022				May 06, 2023
Interest rate per annum after maturity date		10%
0.25% Promissory Notes [Member] | NC 143 [Member] | RLOC [Member]
Debt Instrument [Line Items]
Borrowed from related parties		$ 180,000
0.25% Promissory Notes [Member] | RMI [Member] | RLOC [Member]
Debt Instrument [Line Items]
Borrowed from related parties		$ 20,000

Payroll Protection Program (Det

Payroll Protection Program (Details Narrative) - CARES Act [Member] - Payroll Protection Program Loan [Member]	Apr. 11, 2020 USD ($)
Debt Instrument [Line Items]
Promissory note principal amount	$ 361,400
Maturity date	Apr. 11, 2022
Interest rate percentage	1%

Economic Injury Disaster Loan (

Economic Injury Disaster Loan (Details Narrative) - Economic Injury Disaster Loan Assistance Program [Member] - USD ($)		3 Months Ended		6 Months Ended
	May 12, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 24, 2021
Debt Instrument [Line Items]
Interest expense		$ 0	$ 1,460	$ 0	$ 2,906
CARES Act [Member]
Debt Instrument [Line Items]
Loan principal amount	$ 150,000					$ 500,000
Interest rate percentage	3.75%					3.75%
Debt instrument frequency of periodic payment				monthly
Debt instrument date of first required payment	May 12, 2021
Installment payments including principal and interest	$ 731
Loan principal and interest payable term	30 years
Increased loan amount						$ 350,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Non-Qualified Stock Option Awards [Member]
Class Of Stock [Line Items]
Stock options, granted	0	0	0	0
Unrecognized compensation expenses on stock options	$ 5,906		$ 5,906
Non-Qualified Stock Option Awards [Member] | Selling, General, Administrative and Other Expenses [Member]
Class Of Stock [Line Items]
Share-based compensation expense	4,102	$ 70,075	16,946	$ 186,023
Restricted Common Stock [Member]
Class Of Stock [Line Items]
Share-based compensation expense	$ 0	$ 0	$ 0	$ 0
Number of shares granted			0
Number of shares, exercised			0
Number of shares forfeited			0

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
No. of Shares, Abstract
No. of Shares, Beginning Balance | shares	1,745,000
No. of Shares, Ending Balance | shares	1,745,000	1,745,000
Exercisable, No. of Shares | shares	1,695,000
Weighted Average Exercise Price, Abstract
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.86
Weighted Average Exercise Price, Ending Balance | $ / shares	0.86	$ 0.86
Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.87
Weighted Average Remaining Contractual Term, Abstract
Weighted Average Remaining Contractual Term, Balance outstanding	6 years 2 months 26 days	6 years 8 months 23 days
Weighted Average Remaining Contractual Term, Exercisable	6 years 2 months 15 days
Aggregate Intrinsic Value, Abstract
Aggregate Intrinsic Value, Balance outstanding | $		$ 12,000

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Awards Activity (Details) - Restricted Stock Awards [Member]	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Shares, Non-vested, Balance	2,574,227
Number of Shares, Granted	0
Number of Shares, Vested	0
Number of Shares, Forfeited	0
Number of Shares, Non-vested, Balance	2,574,227
Share-based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value [Abstract]
Fair Value, Non-vested, Balance | $	$ 1,332,100
Fair Value, Non-vested, Balance | $	$ 1,332,100
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Non-vested, Balance | $ / shares	$ 0.52
Weighted Average Grant Date Fair Value, Non-vested, Balance | $ / shares	$ 0.52

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Current:
Federal			$ 0	$ 0
State			10,027	9,186
Income tax expense			10,027	9,186
Deferred:
Federal			0	0
State			0	0
Income tax expense			0	0
Total income tax expense (benefit)	$ 5,171	$ 4,826	$ 10,027	$ 9,186

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryover	$ 1,439,042	$ 1,262,269
Accounts receivable	83,090	104,635
Compensation	559,495	555,936
Inventory	454,371	523,131
Other	20,019	1,244
Total deferred tax assets	2,556,017	2,447,215
Deferred tax liabilities:
Intangibles	(194,809)	(198,801)
Property and equipment	(19,481)	(1,522)
Total deferred tax liabilities	(214,290)	(200,323)
Deferred tax assets, net	2,341,727	2,246,892
Valuation allowance:
Beginning of year	(2,246,892)	(1,816,546)
Increase during the year	(94,835)	(430,346)
Ending balance	(2,341,727)	(2,246,892)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 94,835		$ 430,346
Deferred tax assets, valuation allowance	2,341,727		$ 2,246,892	$ 1,816,546
Net operating loss carryforwards	$ 6,852,583
Net operating loss carryforwards earliest expiration year	2022
Net operating loss carryforwards latest expiration year	2038
Effective income tax rates	(2.30%)	(1.80%)
IRC Section 382 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 2,122,191
Operating Carryforwards Expiration Date from 2022 to 2038 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 1,741,108

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at U.S. Statutory Rate to Effective Income Tax Rate (Details)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Expected U.S. federal incomes as statutory rate	21%	21%
Gain on Payroll Protection Loan	0%	14.50%
Permanent differences	0%	0%
State and local income taxes, net of federal benefit	(1.80%)	(1.40%)
Change in deferred tax asset valuation allowance	(21.50%)	(35.90%)
Effective tax rate	(2.30%)	(1.80%)

Concentrations - Significant Cu

Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling Ten Percent (10%) or Greater (Details) - Revenues [Member] - Customer Concentration Risk [Member]	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Customer 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	11.24%	0.12%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	1.78%	17.05%
Group of Customers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.02%	17.17%

Concentrations - Significant _2

Concentrations - Significant Customers with Concentration of Accounts Receivable Representing Ten Percent (10%) or Greater of Accounts Receivable (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Customer 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.65%	1.84%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	4.53%	13.46%
Customer 3 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	3.72%	11.21%
Group of Customers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	21.90%	26.51%

Concentrations - Significant Su

Concentrations - Significant Suppliers Represented Ten Percent (10%) or Greater of Goods Purchased (Details) - Goods Purchased [Member] - Supplier Concentration Risk [Member]	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Supplier 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	20.64%	21.90%
Supplier 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	11.07%	12%
Group of Suppliers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	31.71%	33.90%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($) ft² FullTimeEquivalent	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
1565 North Central Expressway, LP [Member]
Related Party Transaction [Line Items]
Area of leased property | ft²	11,500
Lease termination date	Dec. 31, 2017
1565 North Central Expressway, LP [Member] | Selling, General, Administrative and Other Expenses [Member]
Related Party Transaction [Line Items]
Rent expense	$ 84,000	$ 84,000
AmBio [Member]
Related Party Transaction [Line Items]
Number of full time equivalents | FullTimeEquivalent	39
Number of full time equivalents directly support company | FullTimeEquivalent	35
Number of full time equivalents support operations of other companies | FullTimeEquivalent	3
Number of full time equivalents shared between company and other companies | FullTimeEquivalent	1
Due to related parties	$ 157,991		$ 170,784
AmBio [Member] | Selling, General, Administrative and Other Expenses [Member]
Related Party Transaction [Line Items]
Administrative fees	97,546	93,000
MedUSA Group, LLC [Member]
Related Party Transaction [Line Items]
Net revenues from related parties	0	1,400
MedUSA Group, LLC [Member] | Stocking and Distribution Agreement [Member]
Related Party Transaction [Line Items]
Due from related parties	0
MedUSA Group, LLC [Member] | Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties	0		63,498
MedUSA Group, LLC [Member] | Commission [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties	1,698,152	1,718,298
MedUSA Group, LLC [Member] | Commission [Member] | Accrued Liabilities [Member]
Related Party Transaction [Line Items]
Due to related parties	1,671,431		923,960
Texas Overlord, LLC [Member]
Related Party Transaction [Line Items]
Due from related parties	0		0
Texas Overlord, LLC [Member] | Accrued Liabilities [Member]
Related Party Transaction [Line Items]
Due to related parties	54,073
Texas Overlord, LLC [Member] | Commission [Member]
Related Party Transaction [Line Items]
Due to related parties	115,000		40,000
Expense incurred on behalf of related parties	75,000	120,000
N.B.M.J., Inc. [Member]
Related Party Transaction [Line Items]
Net revenues from related parties	350	71,381
Due from related parties	2,430		2,080
N.B.M.J., Inc. [Member] | Stocking and Distribution Agreement [Member]
Related Party Transaction [Line Items]
Due from related parties	2,430
Bass Bone And Spine Specialists [Member]
Related Party Transaction [Line Items]
Net revenues from related parties	19,985	23,227
Bass Bone And Spine Specialists [Member] | Stocking and Distribution Agreement [Member]
Related Party Transaction [Line Items]
Due from related parties	13,298
Bass Bone And Spine Specialists [Member] | Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties	15,148		8,413
Sintu L L C | Commission [Member]
Related Party Transaction [Line Items]
Due to related parties	811,197		557,228
Expense incurred on behalf of related parties	253,969	209,089
Tiger Orthopedics, LLC [Member]
Related Party Transaction [Line Items]
Net revenues from related parties	0	502
Due from related parties	0	0
Tiger Orthopedics, LLC [Member] | Stocking and Distribution Agreement [Member]
Related Party Transaction [Line Items]
Due from related parties	0
Modal Manufacturing, LLC [Member] | Stocking and Distribution Agreement [Member]
Related Party Transaction [Line Items]
Due to related parties	848,443
Modal Manufacturing, LLC [Member] | Inventory [Member]
Related Party Transaction [Line Items]
Purchases from related parties	343,713	$ 368,443
Modal Manufacturing, LLC [Member] | Account Payables [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 877,789		$ 709,234